A woman in Oxford has become the first British volunteer to be injected with an experimental Ebola vaccine, which, if it works, will be fast-tracked for use in west Africa.
In an unprecedented move, the untested vaccine has already gone into mass production. Some 10,000 doses are being manufactured by the British drug company GlaxoSmithKline, funded by the Wellcome Trust and the UK government, which are also supporting the Oxford trial.
If the vaccine is found to be effective, there will be supplies available to protect thousands of health workers in west Africa, who will be the first to get it. Nobody wants a repeat of the ZMapp experience – only a dozen doses were available worldwide of the experimental drug and, controversially, they went mostly to foreign medical and aid workers.
The first British volunteer is Ruth Atkins, 48, a communications and engagement manager in the NHS from Marcham in Oxfordshire and a former nurse. She heard on the radio as she was driving home from work that volunteers were needed for a vaccine trial run by Oxford University researchers.
“I volunteered because the situation in west Africa is so tragic and I thought being part of this vaccination process was something small I could do to hopefully make a huge impact,” she said.
One hour after the vaccination, she said: “I feel absolutely fine, it felt no different to being vaccinated before going on holiday.”
Atkins is the first of 60 healthy people who will be vaccinated to find out whether the potential vaccine has any troublesome side effects. Studies involving animals have shown no ill effects so far.
The vaccine was already under development by GSK – it was in the portfolio of Okairos, a smaller company bought by GSK last year – before the Ebola outbreak occurred, but it could have taken a decade to get it through the trials and into production.
Instead, four trials will be taking place at the same time to gather enough safety data and early information on the immune response, which is some indication of whether it really will protect against the disease.
Ten volunteers have already been injected in the US, where the National Institutes of Health has been funding the development of this vaccine against the Ebola Zaire strain and another against Ebola Sudan. If all goes well, there will also be trials in the Gambia and Mali in healthy volunteers.
It is hoped that results from the trials will be available before the end of this year. If the vaccine performs well, it will be given to health workers in Ebola-stricken regions. This, too, is effectively a trial – the only way to find out whether the vaccine really can protect against the disease.
Prof Adrian Hill, director of the Jenner Institute at the University of Oxford which is running the trial, said: “Witnessing the events in Africa makes it clear that developing new drugs and vaccines against Ebola should now be an urgent priority. It is tremendous that so many people have worked hard to make this trial happen in a short time, and I am enormously grateful to those volunteers who have come forward to take part and to the funders including the Wellcome Trust, DFID, MRC and MHRA for supporting this trial so quickly.
“These are initial safety trials of the vaccine and it will be some time before we know whether the vaccine could protect people against Ebola. But we are optimistic that the candidate vaccine may prove useful against the disease in the future.”
Dr Ian Hudson, the Medicines and Healthcare Products Regulatory Agency’s chief executive, said the trial proposal was approved with extraordinary speed: “Our priority is to protect public health. Given the importance of Ebola as a risk to public health in some countries in Africa, we fast-tracked the review of the clinical trial application for this vaccine so that it was assessed and authorised by the MHRA’s experts in just four working days.”